# Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

> **NCT03994783** · PHASE3 · TERMINATED · sponsor: **Imperial College London** · enrollment: 3 (actual)

## Conditions studied

- Kidney Transplant Rejection
- Antibody-mediated Rejection

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Methylprednisolone
- **DRUG:** Intravenous Immunoglobulin
- **PROCEDURE:** Plasma Exchange

## Key facts

- **NCT ID:** NCT03994783
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-17
- **Primary completion:** 2021-07-17
- **Final completion:** 2023-01-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Stopped at start of COVID-19 pandemic - non-feasible
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994783, "Transplant Antibody-Mediated Rejection: Guiding Effective Treatments". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03994783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*